title: Disruptive reproductive technologies.
abstract: In vitro gametogenesis raises new possibilities for reproductive and regenerative medicine as well as vexing policy challenges.
authors.affiliation: Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, Harvard Law School, Cambridge, MA 02138, USA. igcohen@law.harvard.edu.
authors.forename: I Glenn
authors.initials: IG
authors.lastname: Cohen
authors.affiliation: Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.|Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
authors.forename: George Q
authors.initials: GQ
authors.lastname: Daley
authors.affiliation: The Warren Alpert Medical School, Brown University, Providence, RI 02906, USA.
authors.forename: Eli Y
authors.initials: EY
authors.lastname: Adashi
mesh_terms: D000818:Animals; D019070:Cell Lineage; D005307:Fertilization in Vitro / Q000639:trends*; D005718:Gametogenesis; D005854:Germ Cells / Q000166:cytology; D006801:Humans; D007246:Infertility / Q000628:therapy*; D051379:Mice; D044968:Regenerative Medicine / Q000639:trends; D012099:Reproductive Techniques; D014481:United States; D014486:United States Food and Drug Administration